Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma

NCT04644250 | Unknown Phase 2

• 1 other identifier: GLYY-EC-NAD-01
• Study Type: interventional
• Target: 32
• Locations: 1 country
• Sites: 1

Brief Summary

Radical resection is thought to be the mainstay of esophageal cancer treatment. Neoadjuvant chemoradiotherapy (CRT) followed by surgery has become the standard treatment option for locally advanced esophageal squamous cell cancer (ESCC). However, only 20% to 40% of patients can achieve pathologic complete response (pCR) after neoadjuvant CRT with favorable prognosis and about 10% of patients have disease progression after chemoradiotherapy. How to improve the the efficacy of neoadjuvant therapy is an important clinical problem to be solved. Immunotherapy targeting the programmed cell death receptor-1（PD-1） /programmed cell death-Ligand 1(PD-L1) checkpoints has demonstrated promising activity in ESCC. In Keynote181 study, for patients with metastatic esophageal squamous cell carcinoma, regardless of PD-L1 expression, pembrolizumab significantly improved overall survival compared with chemotherapy. However, the efficacy and safety of immunotherapy therapy in surgery-based multidisciplinary treatment of local advanced esophageal cancer still need a lot of clinical studies to further confirm. This study aims to investigate the safety and efficacy of Toripalimab combined with radiotherapy and chemotherapy in neoadjuvant treatment of locally advanced esophageal squamous cell carcinoma

Conditions

Esophageal Squamous Cell Carcinoma

Keywords

Locally advanced esophageal squamous cell carcinoma; Neoadjuvant chemoradiotherapy; Radical resection; Toripalimab

Outcome Measures

Primary Outcomes (1)

• Pathologic complete response rate

  Pathologic complete response was defined as pT0N0M0（clinical stage). The rate of pathologic complete response rate after neoadjuvant chemoradiotherapy.

  Three working days after surgery

Secondary Outcomes (6)

• Incidence of Treatment-related Adverse Events as Assessed by CTCAE v4.0

  From the enrollment to the date of surgery

• 2-year overall survival

  From date of randomization until the date of death from any cause or the date of last follow-up, whichever came first, assessed up to 24 months

• 2-year disease-free survival

  From date of surgery until the date of death from any cause or the date of first documented disease progression whichever came first, assessed up to 24 months.

• Major Pathological Response (MPR) rate

  From date of surgery to 14 days later

• Objective Response Rate (ORR)

  At the end of Cycle 2 (each cycle is 21 days)

Study Arms (1)

Arm1

EXPERIMENTAL

Arm1:preoperative Toripalimab with chemoradiotherapy group Participants will receive carboplatin (AUC=2) VD 30min and paclitaxel liposome (50mg/m²) CIV 24h on day 3,10,17,24,31. And radiotherapy will start from day 1 to 31 of chemotherapy. A total of 41.4 Gy, 23 fractions of 1.8 Gy. Participants will also receive Toripalimab(240mg) VD 30 min on days 3, 24 and 45. After the above neoadjuvant therapy is over, the short-term efficacy evaluation will be performed first, and then a scheduled radical radical resection will be performed from days 59 to 73.

Drug: Toripalimab; Drug: Paclitaxel liposome/Carboplatin; Radiation: Intensity-modulated radiotherapy

Interventions

Toripalimab DRUG

Participants will also receive Toripalimab(240mg) VD 30 min on days 3, 24 and 45，3 cycles in total.

Also known as: JS-001

Arm1

Paclitaxel liposome/Carboplatin DRUG

Participants will receive carboplatin (AUC=2) VD 30min and paclitaxel liposome (50mg/m²) CIV 24h on day 3,10,17,24,31, 5cycles in total.

Also known as: PCb

Arm1

Intensity-modulated radiotherapy RADIATION

A total of 41.4 Gy, 23 fractions of 1.8 Gy on Day 1 to 31.

Also known as: IMRT

Arm1

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Aged 18 to 70 years old of either gender
• A histopathological diagnosis of resectable thoracic esophageal squamous cell carcinoma(The midpoint of the upper and lower margins of the primary tumor is ≥25cm from the incisor)
• There is no distant metastasis and the esophageal tumor can be resected or potentially resectable after the expert consultation of thoracic surgery. The clinical stage is cT3-4aN0-2M0, patients with stage Ⅱ, Ⅲ, and IVA (AJCC 8th edition cTNM staging);
• ECOG PS score of 0-1;
• Patients who are anti-tumor treatment-naive;
• Estimated life expectancy \>6 months
• Baseline the function of important organs meets the following requirements: a. white blood cell count (WBC) ≥ 3×109/L, absolute neutrophil count (ANC) ≥ 1.5×109/L，;Baseline organ function meets: ①WBC≥3×109/L, ANC≥1.5×109/L, PLT≥100×109/L, Hb≥90g/L; ②Liver function: TBIL≤2ULN, Aspartate aminotransferase（AST） ≤2.5ULN, ALT≤2.5ULN ③renal function: cCr≥60 ml/min, Cr≤1.5 ULN; ④heart function: no heart disease or coronary heart disease, the patient's heart function is 1-2 grade;
• The blood pressure of hypertensive patients should be controlled within the normal range with antihypertensive drugs;
• The fasting blood-glucose of diabetic patients should be controlled at ≤8mmol/L through hypoglycemic drugs;
• No other serious diseases that conflict with this plan (such as autoimmune diseases, immunodeficiency, organ transplantation, or other diseases that require continuous hormone therapy);
• No history of other malignant tumors;
• The patient agrees to participate in this clinical study and signs the "Informed Consent". Ability to understand the study and sign informed consent.

You may not qualify if:

• Patients who have been treated previously with anti-tumor therapy (including chemotherapy, radiotherapy, surgery, immunotherapy, etc.);
• Patients with other malignant tumors (non-malignant black skin tumors, cervical cancer in situ, except for cured prostate cancer);
• Patients who have been or expected to have a significant risk of esophageal perforation, fistula, and major bleeding;
• Patients who have active autoimmune diseases or patients who are undergoing treatment of autoimmune diseases (Prior therapy with immunosuppressant, the dose of immunosuppressant used ≥10mg/day, oral prednisone for more than 2 weeks);.
• Uncontrolled clinically significant cardiovascular and cerebrovascular diseases , including but not limited to severe acute myocardial infarction, unstable or severe angina pectoris, coronary artery bypass surgery, congestive heart failure, ventricular arrhythmia requiring medical intervention within 6 months before enrollment 、Left ventricular ejection fraction \<50%, or other patients who are not expected to tolerate chemotherapy and radiotherapy;Cardiac clinical symptoms or diseases that are not well controlled, such as: a. Heart Failure（New York Heart Association）\> Class Ⅱ, b. unstable angina, c. myocardial infarction within 1 year; d. Clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention.
• Patients who were severe allergic constitution;;
• Patients who were pregnant or lactating women;
• Patients who have severe mental disorders;
• Patients who have peripheral nerve disease with common terminology criteria (CTC）grade ≥3;
• Abnormal blood coagulation function including PT\>16s, activated partial thromboplastin time（APTT）\>53s, Thrombin time（TT）\>21s, Fib\<1.5g/L, bleeding tendency or receiving thrombolytic or anticoagulant therapy;
• Patients who hsve severe pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, severely impaired lung function, etc past or present., or active tuberculosis within 1 year;
• Patients who have active hepatitis B or C;
• Patients who did not meet the enrollment conditions xia researchers evaluated.

Sponsors & Collaborators

• Wei Ren: lead

Study Sites (1)

Nanjing Drum Tower Hospital

Nanjing, Jiangsu, 210000, China

RECRUITING

MeSH Terms

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

toripalimab; Carboplatin; Radiotherapy, Intensity-Modulated

Condition Hierarchy (Ancestors)

Carcinoma, Squamous Cell; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Squamous Cell; Esophageal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Head and Neck Neoplasms; Digestive System Diseases; Esophageal Diseases; Gastrointestinal Diseases

Intervention Hierarchy (Ancestors)

Coordination Complexes; Organic Chemicals; Radiotherapy, Conformal; Radiotherapy, Computer-Assisted; Radiotherapy; Therapeutics

Central Study Contacts

Wei Ren

CONTACT

13915981834; renwei@njglyy.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: clinical professor

Study Record Dates

• First Submitted: November 16, 2020
• First Posted: November 25, 2020
• Study Start: September 1, 2020
• Primary Completion: March 1, 2022
• Study Completion: March 1, 2024
• Last Updated: November 25, 2020

Record last verified: 2020-11

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)